

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>Priest Brady Patrick</u>			2. Date of Event Requiring Statement (Month/Day/Year) <u>07/18/2022</u>			3. Issuer Name and Ticker or Trading Symbol <u>CLOVER HEALTH INVESTMENTS, CORP./DE [CLOV]</u>			
(Last)	(First)	(Middle)	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director _____ 10% Owner _____ <input checked="" type="checkbox"/> Officer (give title below) _____ Other (specify below) _____ <u>CEO of Home Care</u>			5. If Amendment, Date of Original Filed (Month/Day/Year)			
<u>C/O CLOVER HEALTH INVESTMENTS, CORP. 3401 MALLORY LANE, SUITE 210</u>						6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person			
(Street)	(City)	(State)	(Zip)						
<u>FRANKLIN</u>	<u>TN</u>	<u>37067</u>							

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date				
Stock Options (right to buy)	(1)	08/09/2026	Class B Common Stock ⁽²⁾	79,349 ⁽¹⁾	1.26	D
Stock Options (right to buy)	(3)	09/12/2027	Class B Common Stock ⁽²⁾	362,252 ⁽³⁾	1.67	D
Stock Options (right to buy)	(4)	09/26/2022	Class B Common Stock ⁽²⁾	60,318 ⁽⁴⁾	3.66	D

Explanation of Responses:

- Received in connection with an August 10, 2016, grant covering 229,349 shares of the Company's Class B common stock. 150,000 shares subject to this grant were exercised and sold prior to the date hereof, and the remaining 79,349 shares subject to the grant are currently vested and exercisable.
- The Class B Common Stock will be convertible into shares of Class A Common Stock on a one-to-one basis at the option of the holders of the Class B Common Stock at any time upon written notice to the Issuer. In addition, the Class B Common Stock will automatically convert into shares of Class A Common Stock immediately prior to the close of business on the earliest to occur of certain events specified in the Issuer's Amended and Restated Certificate of Incorporation.
- Received in connection with a September 13, 2017, grant covering 362,252 shares of the Company's Class B common stock. 100% of the shares subject to this grant are currently vested and exercisable.
- Received in connection with a June 29, 2020, grant covering 103,302 shares of the Company's Class B common stock. 43,085 shares subject to this grant were canceled prior to the date hereof, and the remaining 60,318 shares subject to the grant are currently vested and exercisable.

Remarks:

Exhibit List: Exhibit 24-Power of Attorney

/s/ Joseph R. Martin, as Attorney-in-Fact 07/19/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

The undersigned as a Section 16 reporting person of Clover Health Investments, Corp. (the "Company"), hereby constitutes and appoints Joseph R (1)execute, deliver and file for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of the Company (2)do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such F (3)seek or obtain, as the undersigned's representative and on the undersigned's behalf, information on transactions in the Company's securities (4)take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever :

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 18th day of July, 2022.

/s/ Brady P. Priest

Name: Brady P. Priest